563 Results

People

  1. Zelenetz
    Zelenetz
  2. Moskowitz
    Moskowitz
  3. Yahalom
    Yahalom
  4. Noy
    Noy
  5. De Angelis
    De Angelis
  6. Perales
    Perales
  7. Abrey
    Abrey
  8. Palomba
    Palomba
  9. Younes
    Younes
  10. Matasar
    Matasar

Groups

  1. Department of Medicine (377)
  2. Hematologic Malignancies, Division of (338)
  3. Center for Hematologic Malignancies (292)
  4. Lymphoma (192)
  5. Survivorship Research (98)
  6. Tow Center for Developmental Oncology (TCDO) (72)
  7. Bone Marrow Transplant (65)
  8. GSK Faculty (60)
  9. Epidemiology and Biostatistics (58)
  10. Adult Leukemia (53)
  1. "rituximab"
Formats
  1. Journal Article (489)
  2. Review (36)
  3. Research Letter (13)
  4. Editorial (9)
  5. Correspondence (6)
  6. Meeting Abstract (4)
  7. Book Section (2)
  8. Conference Paper (2)
  9. Guidelines (2)
Groups
  1. Department of Medicine (377)
  2. Hematologic Malignancies, Division of (338)
  3. Center for Hematologic Malignancies (292)
  4. Lymphoma (192)
  5. Survivorship Research (98)
  6. Tow Center for Developmental Oncology (TCDO) (72)

More Groups

People
  1. Andrew Zelenetz (87)
  2. Craig Moskowitz (52)
  3. Joachim Yahalom (39)
  4. Ariela Noy (35)
  5. Lisa De Angelis (32)
  6. Paul Hamlin (32)

More People

Years
  1. 2025 (21)
  2. 2024 (36)
  3. 2023 (36)
  4. 2022 (28)
  5. 2021 (14)
  6. 2020 (25)

More Years

Publications
  1. Blood (43)
  2. Leukemia and Lymphoma (38)
  3. Journal of Clinical Oncology (32)
  4. Haematologica (21)
  5. British Journal of Haematology (20)
  6. Journal of the National Comprehensive Cancer Network (16)

More Publications

Publishers
  1. Elsevier Inc. (70)
  2. American Society of Hematology (61)
  3. Taylor & Francis Group (44)
  4. Springer (42)
  5. American Society of Clinical Oncology (36)
  6. Nature Publishing Group (28)

More Publishers

Results (563)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: Data from the observational National LymphoCare Study
    Research Letter

    Link, B. K.; Day, B. M.; Zhou, X.; Zelenetz, A. D.; Dawson, K. L.; Cerhan, J. R.; Flowers, C. R.; Friedberg, J. W.
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study
    Journal Article

    Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant
    Journal Article

    Vardhana, S.; Hamlin, P. A.; Yang, J.; Zelenetz, A.; Sauter, C. S.; Matasar, M. J.; Ni, A.; Yahalom, J.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
    Journal Article

    Modelevsky, L.; Tizon, R.; Reiss, S. N.; Smith, M.; Garonce, R.; Kaley, T.
    CNS Oncology (2018)

    Fulltext@MSK | Save
  • Hypersensitivity reactions: Priming practice change to reduce incidence in first-dose rituximab treatment
    Journal Article

    Laudati, C.; Clark, C.; Knezevic, A.; Zhang, Z.; Barton-Burke, M.
    Clinical Journal of Oncology Nursing (2018)

    Fulltext@MSK | Save
  • Ibrutinib/rituximab versus placebo/rituximab: A randomized, phase 3 trial in Waldenström's macroglobulinemia (iNNOVATE)
    Meeting Abstract

    Palomba, M. L.; Dimopoulos, M. A.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • First-generation and second-generation Bruton tyrosine kinase inhibitors in Waldenström macroglobulinemia
    Journal Article

    Argyropoulos, K. V.; Lia, M.
    Hematology/Oncology Clinics of North America (2018)

    Fulltext@MSK | Save
  • Improving outcomes in primary CNS lymphoma
    Journal Article

    Graham, M. S.; DeAngelis, L. M.
    Best Practice and Research: Clinical Haematology (2018)

    Fulltext@MSK | Save
  • Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Journal Article

    Geyer, M. B.; Rivière, I.; Sénéchal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Halton, E.; Lamanna, N.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Journal Article

    Dang, N. H.; Ogura, M.; Castaigne, S.; Fayad, L. E.; Jerkeman, M.; Radford, J.; Pezzutto, A.; Bondarenko, I.; Stewart, D. A.; Shnaidman, M.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save